Sutro BiopharmaSTRO
STRO
0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
263% more call options, than puts
Call options by funds: $243K | Put options by funds: $67K
5% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 37
0.72% more ownership
Funds ownership: 76.35% [Q3] → 77.07% (+0.72%) [Q4]
7% less funds holding
Funds holding: 130 [Q3] → 121 (-9) [Q4]
23% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 30
46% less capital invested
Capital invested by funds: $217M [Q3] → $117M (-$99.7M) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$1
68%
upside
Avg. target
$1.67
180%
upside
High target
$2
236%
upside
3 analyst ratings
0 positive
0%
2 neutral
67%
1 negative
33%
HC Wainwright & Co. Andrew Fein 32% 1-year accuracy 113 / 358 met price target | 236%upside $2 | Neutral Downgraded | 17 Mar 2025 |
Wedbush David Nierengarten 35% 1-year accuracy 42 / 119 met price target | 236%upside $2 | Neutral Downgraded | 14 Mar 2025 |
B of A Securities Tazeen Ahmad 26% 1-year accuracy 9 / 34 met price target | 68%upside $1 | Underperform Downgraded | 14 Mar 2025 |
Financial journalist opinion
Based on 6 articles about STRO published over the past 30 days
Neutral
GlobeNewsWire
2 weeks ago
Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025
- The late-breaking oral presentation at SGO 2025 highlights consistent response rates observed in patients across all levels of FRα expression of 25% or greater - - The late-breaking oral presentation at SGO 2025 highlights consistent response rates observed in patients across all levels of FRα expression of 25% or greater -
Negative
Benzinga
2 weeks ago
Penny Stock Sutro Biopharma Cuts Costs, Refocuses Pipeline
On Thursday, Sutro Biopharma, Inc. STRO prioritized its antibody-drug conjugates (ADC) pipeline, including three wholly-owned preclinical programs in its next-generation ADC pipeline.
Negative
Zacks Investment Research
2 weeks ago
Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Tops Revenue Estimates
Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.89 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to earnings of $0.42 per share a year ago.
Neutral
GlobeNewsWire
2 weeks ago
Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights
– Sutro announced a strategic portfolio review resulting in prioritization of wholly-owned next-generation ADC programs; Key management changes announced as part of transition –
Neutral
GlobeNewsWire
2 weeks ago
Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline
– Sutro will rapidly advance next-generation exatecan and dual-payload ADC programs; luveltamab tazevibulin development to be deprioritized as Sutro continues to seek a partner –
Neutral
GlobeNewsWire
4 weeks ago
Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will present at the TD Cowen 45th Annual Health Care Conference taking place March 3-5, 2025 in Boston, MA.
Neutral
GlobeNewsWire
2 months ago
Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 2:15 p.m. PT / 5:15 p.m. ET in San Francisco, CA.
Neutral
Seeking Alpha
2 months ago
Sutro Biopharma: I Don't Buy That Their Pipeline Is Worthless
STRO's valuation remains compelling despite recent market hits, with optimism for a turnaround driven by late-stage clinical trials and strong pipeline potential. Luveltamab tazevibulin shows promising efficacy in ovarian cancer, with manageable toxicity, positioning it for potential Accelerated Approval by mid-2027. Financially, STRO has a two-year runway with current cash reserves, but further financing may be needed, risking shareholder dilution.
Positive
Zacks Investment Research
4 months ago
Sutro Biopharma (STRO) Upgraded to Buy: Here's What You Should Know
Sutro Biopharma (STRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Negative
Zacks Investment Research
4 months ago
Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Misses Revenue Estimates
Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.74. This compares to loss of $0.81 per share a year ago.
Charts implemented using Lightweight Charts™